Men's Health Women's Health Senior's Health Antioxidants Sports Nutrition Diet & Weight Loss Vitamins & Minerals Herbs Specialty Supplements Targeted Supplements Spa Products Anti-Aging Basics Body Systems Body Structure Book Store Pet Health My Recommendation My Favorite Articles Our Most Popular Specials Bargain Basement Brands Free Samples

MSM

Health News Archive 25 - Fibromyalgia
<<back to structure/function index

• CMO (Cetyl Myristoleate) in the Treatment of Fibromyalgia: An Open Pilot Study

CMO (Cetyl Myristoleate) in the Treatment of Fibromyalgia: An Open Pilot Study

Purpose: To investigate the efficacy and tolerability of CMO (cerasomol-cis-9-cetyl myristoleate) in the treatment of fibromyalgia.

Design: Open study: 21 days' treatment following a 7-day baseline without treatment.

Materials and Methods: Thirteen adult patients with fibromyalgia. Following a 7-day pre-treatment baseline, patients were treated with a mixture of CMO + sea cucumber and shark cartilage extracts. All treatments were administered orally. Fibromyalgia patients kept daily diary cards recording the severity of generalized pain, fatigue and sleep disturbance (scale 0-4). A symptom profile was made using an 84-point questionnaire. Adverse events were recorded.

Results: Ten fibromyalgia patients completed the study. One subject did not record baseline symptoms. Two patients had to discontinue treatment because of adverse effects. One patient had severe indigestion and the other developed muscle spasms and a skin rash. The mean (and corresponding Standard Deviation) scores for the severity of pain, fatigue, and sleep disturbance during the baseline were 2.63 (0.55), 2.50 (0.54) and 2.33 (0.480). These improved to 1.70 (0.82), 1.83 (0.82) and 1.73 (1.11) during the last 7 days of CMO treatment. There were individual differences in CMO treatment response with five patients showing good response and five showing little or no response. From the questionnaires, those showing the best CMO response had more severe pain and cognitive dysfunction than the non-responders. In addition to the two withdrawals, one further fibromyalgia patient reported gastrointestinal symptoms.

Conclusions: This open study provides evidence of a beneficial effect of CMO in the treatment of fibromyalgia. A double-blind, placebo-controlled study is now required to confirm this. This should also include a symptom profile questionnaire, which may help to distinguish responders and non-responders.

Journal of Nutritional & Environmental Medicine, Jun 2001, Vol. 11 Issue 2, p105, 7p, 2 graphs

back to top